UBS upgrades JAZZ from Neutral to Buy

The Rating Action

UBS upgraded Jazz Pharmaceuticals (JAZZ) from Neutral to Buy on 2026-05-19. The company has a $14.9B market capitalization, with shares trading at $237.45 at the time of the rating update. Cited news headlines reference a $307 implied price target, but this figure is not included in the provided research context.

Coverage History & Consensus

Prior to the May 19 upgrade, UBS held a Neutral rating, which aligns with the "Hold" tier in the tracked analyst distribution. As of May 1, 2026, the broader analyst consensus for JAZZ split 6 Strong Buy, 9 Buy, and 2 Hold ratings, with no Sell or Strong Sell coverage. UBS’s shift to Buy moves the firm in line with the 15 total Buy/Strong Buy analysts, leaving only 1 remaining Hold-rated analyst assuming UBS was one of the two Hold-rated firms tracked on May 1, 2026.

Cross-Reference to Fundamentals & Insider Activity

The upgrade follows two key recent developments for JAZZ: first, the company’s May 5, 2026, earnings report, where it posted a 35.8% EPS beat (actual $6.34 vs consensus $4.67) and a 9.2% revenue beat (actual $1.069B vs consensus $978.7M). Second, director Bruce Cozadd sold 6,000 JAZZ shares via a May 5, 2026, Form 4 filing, for $1,219,980 at a per-share price of $203.33, marking his third reported sale in 2026 following in-kind stock grants to executive leadership in March 2026. The latest institutional 13F filing, as of December 31, 2025, shows 592 institutional holders (up 75 quarter-over-quarter) holding 101.5% of the company’s float, with 309 firms increasing positions and only 194 reducing holdings.

What This Rating Change Does NOT Signal

1. It does not include a confirmed official price target, as the provided research context only references a headline-cited $307 figure with no official UBS target disclosed.

2. It does not reflect new institutional positioning shifts, as the latest 13F data is dated December 31, 2025, five months prior to the May 19 rating update.

3. It does not tie to the May 19 RBC Capital Markets conference transcript, as UBS’s rating action was not linked to new conference-specific data in the provided research context.